Negative Antiamyloid Drug Trial: Lessons Learned
-
The investigational antiamyloid monoclonal antibody crenezumab (Genentech) is not superior to placebo for change in cognition, brain imaging, or biomarker outcomes in individuals who are at genetically high risk for Alzheimer's disease (AD), new research shows.
-
@ricky Results from a CSF amyloid oligomeric assay to determine target engagement as well as pharmacokinetic/pharmacodynamic analyses to measure drug exposure are still in progress.